核心观点 - 阿联酋私营医疗公司Pharma 1已向阿联酋卫生部提交申请，寻求批准商业化Evofem Biosciences的激素避孕凝胶PHEXXI，目标在2026年第一季度在阿联酋上市 [1] - Pharma 1计划于2025年7月下达PHEXXI的首批订单，以支持产品在阿联酋的上市 [1] - PHEXXI是美国FDA批准的首个且唯一一种局部作用的避孕凝胶，不含激素，通过调节阴道pH值发挥作用 [4] 公司动态 Evofem Biosciences - 公司正在通过战略合作伙伴关系拓展全球市场，与Pharma 1的许可协议预计将使PHEXXI和SOLOSEC于2026年在阿联酋上市 [6] - 2024年是公司连续第四年实现净销售额增长，商业团队在2024年11月重新推出了SOLOSEC，并与PHEXXI一起向美国妇产科医生推广 [6] - SOLOSEC是一种FDA批准的口服抗生素，用于治疗细菌性阴道病和滴虫病，单剂量即可完成疗程 [5] Pharma 1 Drug Store - 公司自2019年成立以来，一直致力于基于科学研究和准确调查提供满足医疗需求的实用解决方案，在海湾合作委员会（GCC）的动态和增长市场中表现出色 [3] - Pharma 1拥有PHEXXI在中东地区（包括阿联酋、科威特、沙特阿拉伯、卡塔尔等）的独家商业化权利，负责所有分销、销售、营销和药物警戒工作 [2] - 公司是多家制药公司的代理商，拥有多种商业产品和正在卫生部审批中的药物 [8][9] 市场与产品 - 市场研究表明，阿联酋及周边地区对无激素、按需避孕的需求正在增长，预计PHEXXI将受到妇产科医生和女性的广泛欢迎 [2] - PHEXXI是一种无激素、非全身性的避孕产品，女性可自行控制并按需使用 [2] - PHEXXI通过预填充给药器在性行为前0-60分钟使用，通过维持阴道微生物组的pH值来抑制精子及某些病毒和细菌病原体 [4]

— Pharma 1 Targets Mid-2025 Regulatory Submission in UAE for SOLOSEC to Treat Bacterial Vaginosis and Trichomoniasis —SAN DIEGO, May 21, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) and private Emirati health care company Pharma 1 Drug Store LLC have signed a License and Supply Agreement for the Middle East rights to SOLOSEC® (secnidazole) 2 g oral granules, Evofem's FDA-approved single-dose oral treatment for two common sexual health conditions.Consideration to Evofe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36754 EVOFEM BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 20-8527075 (State or other juris ...

Exhibit 99.1 Evofem Reports First Quarter 2025 Financial Results and Provides Business Update SAN DIEGO, CA, May 15, 2025 — Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter ended March 31, 2025. "Quarterly fluctuations are normal for our business, which is why we focus on driving annual growth," said Saundra Pelletier, Evofem's CEO. "First quarter net sales were soft, as expected, due to the high level of PHEXXI stocking orders in the f ...

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter ended March 31, 2025."Quarterly fluctuations are normal for our business, which is why we focus on driving annual growth," said Saundra Pelletier, Evofem's CEO. "First quarter net sales were soft, as expected, due to the high level of PHEXXI stocking orders in the fourth quarter of 2024, ahead of the annual price increase in January as well as large ...

— 2024 Net Sales Increased 6% to $19.4 Million — — Total Operating Expense Reduced 27% from 2023 Levels, Excluding Non-cash Amortization Expense — Evofem Reports Fourth Consecutive Year of Net Sales Growth — Sales and Marketing Expense as a Percentage of Net Sales was 47% for 2024 and 31% for the Fourth Quarter, the Most Favorable Ratios since the PHEXXI Launch — SAN DIEGO, CA, March 24, 2025 — Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36754 EVOFEM BIOSCIENCES, INC. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______ to ______ Commission File Number: 001-36754 EVOFEM BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 20-8527075 (Sta ...

Exhibit 99.1 Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 — Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, CA, November 14, 2024 — Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the third quarter an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36754 EVOFEM BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 20-8527075 (State or other jurisd ...